Detail akcie Revance Therap online

Business Summary: Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Revance Therapeutics Inc revenues increased 17% to $117.3M. Net loss before extraordinary items decreased 18% to $87M. Revenues reflect Collaboration revenue increase from $136K to $278K. Lower net loss reflects Stock based compensation decrease of 46% to $12.1M (expense), Stock-based Compensation in R&D decrease of 58% to $2.6M (expense).